$TVGN

Tevogen Bio announces capital discipline measures including lead investor holding commitment, restricting share issuance to 1% of authorized shares, and targeting $50M+ revenue acquisitions.

Tevogen Bio ($TVGN) expands T-cell therapy coverage to 65% of U.S. population and pursues digital care platform acquisition to advance Long COVID treatment.

Tevogen Bio ($TVGN) pursues Apozeal acquisition to bolster generics platform; stock plunges 15.41% despite initial rally, trading at 52-week lows amid strategic uncertainty.

Tevogen Bio ($TVGN) targets Apozeal Pharmaceutical acquisition to gain 11 FDA-approved generics and strengthen domestic drug manufacturing.

Tevogen Bio signs Letter of Intent to acquire Apozeal Pharmaceutical, gaining 11 FDA-approved generics and pipeline assets to expand domestic manufacturing strategy.

Tevogen Bio pursues Sciometrix acquisition to integrate digital care management platform with its AI initiatives, aiming to become a revenue-generating healthcare enterprise.

Tevogen Bio pursues acquisition of Sciometrix to gain Clinicus digital care platform, integrating it with its AI division to expand into healthcare services alongside biotech operations.